Investigation of the transport of xanthine dehydrogenase inhibitors by the urate transporter ABCG2.

Article Details

Citation

Copy to clipboard

Nakamura M, Fujita K, Toyoda Y, Takada T, Hasegawa H, Ichida K

Investigation of the transport of xanthine dehydrogenase inhibitors by the urate transporter ABCG2.

Drug Metab Pharmacokinet. 2018 Feb;33(1):77-81. doi: 10.1016/j.dmpk.2017.11.002. Epub 2017 Nov 22.

PubMed ID

29342419 [ View in PubMed

]

Abstract

Hyperuricemia induces gout and kidney stones and accelerates the progression of renal and cardiovascular diseases. Adenosine 5'-triphosphate-binding cassette subfamily G member 2 (ABCG2) is a urate transporter, and common dysfunctional variants of ABCG2, non-functional Q126X (rs72552713) and semi-functional Q141K (rs2231142), are risk factors for hyperuricemia and gout. A recent genome wide association study suggested that allopurinol, a serum uric acid-lowering drug that inhibits xanthine dehydrogenase, is a potent substrate of ABCG2. In this study, we aimed to examine the transport of xanthine dehydrogenase inhibitors via ABCG2. Our results show that ABCG2 transports oxypurinol, an active metabolite of allopurinol, whereas allopurinol and febuxostat, a new xanthine dehydrogenase inhibitor, are not substrates of ABCG2. The amount of oxypurinol transported by ABCG2 vesicles significantly increased in the presence of ATP, compared to that observed with mock vesicles. Since the half-life of oxypurinol is longer than that of allopurinol, the xanthine dehydrogenase-inhibiting effect of allopurinol mainly depends on its metabolite, oxypurinol. Our results indicate that the serum level of oxypurinol would increase in patients with ABCG2 dysfunction.

DrugBank Data that Cites this Article

Drug Transporters

Drug	Transporter	Kind	Organism	Pharmacological Action	Actions
Allopurinol	ATP-binding cassette sub-family G member 2	Protein	Humans	Unknown	Substrate	Details